Overview
CSL of Melbourne manufactures, markets and distributes biopharmaceutical products through three segments: CSL Behring, CSL Seqirus and CSL Vifor.[2] CSL Behring provides plasma products, gene therapies and recombinant products; CSL Seqirus sells mainly influenza vaccines and provides pandemic services to governments; and CSL Vifor distributes products for iron deficiency and nephrology.[2] Forbes records sales of US$15.3bn, up 1.1%, and profit of US$1.4bn.[2] It is the only Australian company in the top 25. CSL Behring works in the same plasma-derived therapies field as Takeda. Forbes counts 29,000 employees and a market value of US$33.6bn.[2]
CSL strengths and limitations
Strengths
- Leading plasma-fractionation business
- Only Australian company in the list
- Diversified into vaccines and nephrology
Limitations
- Sales growth of 1.1%
- Profit margin under 10%
- Plasma collection is costly and capacity-bound
Appears in
CSL peers and competitors
Companies ranked in the same lists as CSL.
BHP Group
GSK plc
Merck & Co.
Pfizer- AbbVie
AstraZeneca PLC
Novartis
Bayer AG
Novo Nordisk
Sanofi- Bristol Myers Squibb
- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.